Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641718 | 0.87 | GRB2 (0.51) | CALCRLGRB2RAMP1BACE1CTSD | |
| SCHEMBL30150572 | 0.85 | ACE (0.47) | CALCRLGRB2RAMP1BACE1CTSD | |
| SCHEMBL30420753 | 0.85 | GRB2 (0.47) | GRB2CXCL8 | |
| SCHEMBL30420502 | 0.85 | GRB2 (0.49) | GRB2BACE1CXCL8CTSD | |
| SCHEMBL30495654 | 0.84 | CALCRL (0.52) | CALCRLGRB2RAMP1BACE1CTSD | |
| SCHEMBL30419987 | 0.84 | GRB2 (0.47) | GRB2CXCL8FNTAFNTB | |
| SCHEMBL30830432 | 0.84 | FNTA (0.44) | CALCRLGRB2BACE1CTSDFNTA | |
| SCHEMBL30262155 | 0.83 | GRB2 (0.43) | GRB2CXCL8F2 | |
| SCHEMBL30304780 | 0.83 | NTSR1 (0.46) | FNTAFNTBF2 | |
| SCHEMBL30131170 | 0.83 | GRB2 (0.47) | GRB2BACE1FNTAFNTBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | CALCRL 62/4885GRB2 666/4885RAMP1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.